Compare DuPont de Nemours Inc (DD) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DuPont de Nemours Inc vs Viatris Inc — how do they compare? DuPont de Nemours Inc trades at $144.26 (market cap $19.51B), while Viatris Inc trades at $16.28 (market cap $18.69B). The key difference: DuPont de Nemours Inc and Viatris Inc are close in size by market cap, and Viatris Inc pays the higher dividend (2.95%). Which is the better fit depends on your goals.
| DD | VTRS | |
|---|---|---|
Market Cap | $19.51B | $18.69B |
Sector | Basic Materials | Health |
52-Week High | $154.59 | $17.86 |
52-Week Low | $90.24 | $9.49 |
Enterprise Value | $20.90B | $30.80B |
Dividend Yield | 1.66% | 2.95% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DuPont de Nemours Inc
DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations. Its portfolio includes specialty chemicals and downstream products that serve the electronics and communication, automotive, construction, safety and protection, and water management industries. DuPont benefits from the ability to produce patented specialty chemicals that command pricing power. Noteworthy products include Kevlar, Tyvek, and Nomex have evolved over time to enable a wide range of applications across multiple industries.
Read more on DD →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
